Skip to content

Optimal dose of topical tranexamic acid for the efficacy and safety of total knee arthroplasty: a randomized controlled study

Optimal dose of topical tranexamic acid for the efficacy and safety of total knee arthroplasty: a randomized controlled study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038219
Enrollment
Unknown
Registered
2020-09-14
Start date
2020-09-13
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total knee arthroplasty

Interventions

Group 1:TXA 0.5 g
Group 2:TXA 1g
Group 3:TXA 2g
Group 4:TXA 3g

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Undergo unilateral TKA for knee osteoarthritis were recruited. TKAs were generally performed to the patients who had degeneration change of Kellgren and Lawrence grade 3 or 4 on X-ray with persisting pain without response to conservative treatment such as drugs or intraarticular injection.

Exclusion criteria

Exclusion criteria: The exclusion criteria were preoperative anemia (hemoglobin level 1.4, or prolonged partial thromboplastin time [> 1.4 times normal]), acquired disturbances of color vision, history of arterial or venous thromboembolic disease (such as a cerebrovascular attack, DVT, or PE), and major comorbidities (including previous myocardial infarction, heart failure, pulmonary disease and renal or hepatic failure). Patients who had not received spinal anesthesia, those with medical complications during anesthesia, surgical complications, such as intraoperative fracture or inevitable use of revision implant, or postoperative management complications, such as non-functional Hemovac drain, were excluded from the study.

Countries

China

Contacts

Public ContactFeng Shuo

Affiliated Hospital of Xuzhou Medical University

xzfs0561@163.com+86 18552880088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026